NASDAQ:KIN Kindred Biosciences (KIN) Stock Price, News & Analysis → A lot of people are making this costly mistake (From WealthPress) (Ad) Free KIN Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$9.24▼$9.2650-Day Range$9.08▼$9.2552-Week Range$3.46▼$9.28Volume178,496 shsAverage Volume840,890 shsMarket Capitalization$420.52 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Kindred Biosciences alerts: Email Address Ad Crypto 101 MediaCrypto Market Preps For Trillions Worth of Inflows! Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.Click to join the Crypto Community Summit Free Online Event About Kindred Biosciences Stock (NASDAQ:KIN)Kindred Biosciences, Inc. is a development-stage biopharmaceutical company, which focuses on saving and improving the lives of pets. The company was founded by Richard Chin and Denise M. Bevers on September 25, 2012 and is headquartered in Burlingame, CA.Read More Ad DTIthe most reliable asset on earth is making a comebackGlobal tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.And you can see how it works for FREE when you Click Here KIN Stock News HeadlinesMarch 22, 2024 | mirror.co.ukTory party donor Frank Hester to be investigated for 'racist comments' by West Yorkshire PoliceFebruary 23, 2024 | health.usnews.comKindred Hospital East GreensboroMarch 28, 2024 | Crypto Swap Profits (Ad)Grab Your Free Bitcoin Today!And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.January 22, 2024 | reuters.comJapan's Sony terminates $10 bln Zee India mergerJanuary 22, 2024 | markets.businessinsider.comEuropean Shares Edge Higher With ECB Meeting In The SpotlightJanuary 22, 2024 | markets.businessinsider.comEarnings Optimism May Contribute To Continued Strength On Wall StreetDecember 17, 2023 | latimes.comHonoree: Nanxi LiuNovember 8, 2023 | finance.yahoo.comGlobal Companion Animal Pharmaceuticals Market Size To Worth USD 27.16 Billion by 2032 | CAGR of 5.7%March 28, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.October 7, 2023 | health.usnews.comKindred Hospital-DaytonSeptember 21, 2023 | tmcnet.comBluejay Therapeutics expands management team and hired Christopher Holterhoff as senior Vice President, head of business developmentAugust 17, 2023 | bizjournals.comHow a small Peninsula company plans to take a big bite out of the pet drug marketJune 11, 2023 | es-us.finanzas.yahoo.comPet Cancer Therapeutics Global Market Report 2023May 11, 2023 | marketwatch.comOral COVID-19 Vaccine Market 2023 Expected Highest Growth and Precise Outlook | Pfizer, CanSino Biologics, Kindred BiosciencesMay 5, 2023 | marketwatch.comPet Medication Market Size and Forecast to 2031May 5, 2023 | health.usnews.comKindred Hospital-New Jersey Morris CountyApril 26, 2023 | uk.finance.yahoo.comVeterinary Dermatology Drugs Global Market Report 2023April 25, 2023 | health.usnews.comKindred Hospital Chicago-NorthlakeApril 19, 2023 | usnews.comKindred High SchoolApril 19, 2023 | thestreet.comKindred Bio CEO: Expect 3 Dynamic Dog Drugs by 2015March 31, 2023 | theguardian.comKindred review – a reductive, hollow view of Black traumaMarch 30, 2023 | marketwatch.comCanine Atopic Dermatitis Market Share and Forecast till 2031March 28, 2023 | health.usnews.comKindred Hospital-OntarioMarch 22, 2023 | marketwatch.comCompanion Animal Pharmaceuticals Market worth $19.6 billion | MarketsandMarketsMarch 7, 2023 | marketwatch.comThe Pet Medication study examines a number of direct and indirect factors that could affect the supply and demand dynamics in this marketMarch 6, 2023 | msn.comHow De La Soul's 3 Feet High and Rising broadened the possibilities of hip hopMarch 3, 2023 | marketwatch.comPet Medication Market 2023 | Global Industry Report Forecast 2029See More Headlines Receive KIN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kindred Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/05/2021Today3/28/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:KIN CUSIPN/A CIK1561743 Webkindredbio.com Phone(650) 701-7901FaxN/AEmployees63Year Founded2013Profitability EPS (Most Recent Fiscal Year)($0.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-21,800,000.00 Net Margins-529.26% Pretax MarginN/A Return on Equity-54.19% Return on Assets-39.76% Debt Debt-to-Equity Ratio0.19 Current Ratio7.02 Quick Ratio7.02 Sales & Book Value Annual Sales$42.16 million Price / Sales9.97 Cash FlowN/A Price / Cash FlowN/A Book Value$1.75 per share Price / Book5.29Miscellaneous Outstanding Shares45,462,000Free FloatN/AMarket Cap$420.52 million OptionableOptionable Beta1.30 Social Links 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesRichard H. ChinPresident, Chief Executive Officer & DirectorWendy WeeSecretary, Chief Financial & Accounting OfficerHangjun ZhanChief Scientific OfficerRussell RadefeldVP-Information Technology & Digital MarketingJay PetersonSenior Director-BiomanufacturingKey CompetitorsShattuck LabsNASDAQ:STTKAkebia TherapeuticsNASDAQ:AKBAAEON BiopharmaNASDAQ:AEONHarrow HealthNASDAQ:HROWPepGenNASDAQ:PEPGView All Competitors KIN Stock Analysis - Frequently Asked Questions How were Kindred Biosciences' earnings last quarter? Kindred Biosciences, Inc. (NASDAQ:KIN) released its earnings results on Thursday, August, 5th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.16) by $0.04. The biopharmaceutical company earned $3.54 million during the quarter, compared to analysts' expectations of $8.12 million. Kindred Biosciences had a negative net margin of 529.26% and a negative trailing twelve-month return on equity of 54.19%. What other stocks do shareholders of Kindred Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Kindred Biosciences investors own include bluebird bio (BLUE), Sorrento Therapeutics (SRNE), Amicus Therapeutics (FOLD), Novavax (NVAX), Rigel Pharmaceuticals (RIGL), Inovio Pharmaceuticals (INO), OPKO Health (OPK), TherapeuticsMD (TXMD) and Agile Therapeutics (AGRX). This page (NASDAQ:KIN) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryFed launches fourth dollar overhaulStansberry ResearchBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kindred Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.